Skip to main content

Table 3 Hazard ratios (95% CI) associated with delays in treatment intensification by 1 year in interaction with poor glycaemic control [HbA1C ≥7% (≥53 mmol/mol) and HbA1C ≥7.5% (≥58 mmol/mol)] consistently during 1 year post diagnosis of diabetes for cardiovascular events

From: Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes

  Without previous CVD HR (95% CI) P With previous CVD HR (95% CI) P All patients HR (95% CI) P
MI
 With HbA1C ≥7% (≥53 mmol/mol)
  A: IT within 1 year 1.37 (1.09, 1.72) <0.01 1.21 (0.81, 1.82) 0.36 1.32 (1.08, 1.61) <0.01
  B: IT after 1 year 1.80 (1.45, 2.22) <0.01 1.34 (0.91, 1.96) 0.13 1.67 (1.39, 2.01) <0.01
 With HbA1C ≥7.5% (≥58 mmol/mol)
  A: IT within 1 year 1.59 (1.27, 1.99) <0.01 1.12 (0.73, 1.71) 0.62 1.47 (1.20, 1.79) <0.01
  B: IT after 1 year 1.56 (1.24, 1.97) <0.01 1.42 (0.95, 2.14) 0.09 1.52 (1.24, 1.86) <0.01
HF
 With HbA1C ≥7% (≥53 mmol/mol)
  A: IT within 1 year 1.14 (0.94, 1.40) 0.19 1.52 (1.09, 2.12) 0.015 1.23 (1.04, 1.46) 0.017
  B: IT after 1 year 1.63 (1.36, 1.96) <0.01 1.66 (1.21, 2.27) <0.01 1.64 (1.40, 1.91) <0.01
 With HbA1C ≥7.5% (≥58 mmol/mol)
  A: IT within 1 year 1.32 (1.07, 1.62) <0.01 1.52 (1.08, 2.13) 0.016 1.37 (1.15, 1.63) <0.01
  B: IT after 1 year 1.61 (1.32, 1.97) <0.01 1.50 (1.06, 2.12) 0.021 1.58 (1.33, 1.88) <0.01
Stroke
 With HbA1C ≥7% (≥53 mmol/mol)
  A: IT within 1 year 1.28 (1.03, 1.60) 0.025 1.80 (1.10, 2.95) 0.019 1.36 (1.12, 1.66) <0.01
  B: IT after 1 year 1.50 (1.22, 1.84) <0.01 1.60 (0.98, 2.60) 0.06 1.51 (1.25, 1.83) <0.01
 With HbA1C ≥7.5% (≥58 mmol/mol)
  A: IT within 1 year 1.27 (1.01, 1.59) 0.040 1.89 (1.16, 3.06) 0.010 1.36 (1.11, 1.67) <0.01
  B: IT after 1 year 1.37 (1.09, 1.71) <0.01 1.34 (0.78, 2.30) 0.28 1.36 (1.11, 1.67) <0.01
Any CVE
 With HbA1C ≥7% (≥53 mmol/mol)
  A: IT within 1 year 1.22 (1.07, 1.38) <0.01 1.36 (1.06, 1.74) 0.015 1.24 (1.11, 1.40) <0.01
  B: IT after 1 year 1.64 (1.45, 1.85) <0.01 1.57 (1.25, 1.98) <0.01 1.62 (1.46, 1.80) <0.01
 With HbA1C ≥7.5% (≥58 mmol/mol)
  A: IT within 1 year 1.32 (1.15, 1.50) <0.01 1.40 (1.09, 1.81) <0.01 1.33 (1.19, 1.50) <0.01
  B: IT after 1 year 1.50 (1.32, 1.71) <0.01 1.50 (1.17, 1.94) <0.01 1.50 (1.33, 1.68) <0.01
  1. The reference group was those with TTIT <12 months and HbA1c <7 or 7.5% (<53 or 58 mmol/mol). A: TTIT <12 months and HbA1c ≥7 or 7.5% (≥53 or 58 mmol/mol), B: TTIT ≥12 months and HbA1c ≥7 or 7.5% (≥53 or 58 mmol/mol). Analyses are based on multivariate Cox-regression models, with contrast matrix to evaluate the effect of delay in treatment intensification in conjunction higher and lower levels of HbA1c at 7 and 7.5% cut offs (53 and 58 mmol/mol).